BMF-500 is under clinical development by Biomea Fusion and currently in Phase I for Relapsed Acute Myeloid Leukemia. According to GlobalData, Phase I drugs for Relapsed Acute Myeloid Leukemia have a 70% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how BMF-500’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
BMF-500 overview
BMF-500 is under development for the treatment of relapsed and refractory acute myeloid leukemia (AML), acute mixed phenotype leukemia (MPAL) and acute lymphocytic leukemia (ALL). They are administered though oral route. The drug candidate acts by targeting third-generation Fms-like tyrosine kinase 3 (FLT3). The drug candidates are being developed based on Fusion System platform.
Biomea Fusion overview
Biomea Fusion is a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers. The company is headquartered in Palo Alto, California, the US.
For a complete picture of BMF-500’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
